Clinical Reviews in Bone and Mineral Metabolism

, Volume 4, Issue 4, pp 277-290

First online:

The use of teriparatide and PTH(1–84) for the treatment of osteoporosis

  • Rachel B. WagmanAffiliated withAmgen IncStanford University School of Medicine Email author 
  • , Paul D. MillerAffiliated withColorado Center for Bone ResearchUniversity of Colorado School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Different therapeutic formulations of parathyroid hormone (PTH) have been studied for the treatment of osteoporosis: synthetic teriparatide [hPTH(1–34)], reconstituted from lysophilized powder; recombinant human teriparatide [rhPTH(1–34)], which has been commercially available since 2002; and PTH(1–84), which is under review by the US Food and Drug Administration (FDA). Teriparatide has demonstrated vertebral and nonvertebral vertebral antifracture efficacy, increases in BMD and biochemical markers of bone turnover, the cornerstones of judging success with an osteoporosis agent. PTH (1–84) may be an alternative consideration for the treatment of both the prevention of the first vertebral fracture as well as the reduction in future vertebral fracture risk in postmenopausal women with existing vertebral fractures. It remains to be seen if there are therapeutic differences between the already approved teriparatide and yet-to-be-approved PTH(1–84).

Key Words

Osteoporosis teriparatide PTH(1–34) PTH (1–84) fracture bone mineral density biochemical markers of bone turnover